Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STVN Stock Forecast 2026-2027
$20.46
Current Price
$5.59B
Market Cap
Buy 8
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to STVN Price Targets
+80.8%
To High Target of $37.00
+36.9%
To Median Target of $28.00
+12.4%
To Low Target of $23.00
STVN Price Momentum
-6.7%
1 Week Change
-3.9%
1 Month Change
-7.6%
1 Year Change
+1.7%
Year-to-Date Change
-26.9%
From 52W High of $28.00
+14.9%
From 52W Low of $17.81
📊 TOP ANALYST CALLS
Did STVN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Stevanato Group is one of their latest high-conviction picks.
Latest STVN Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, STVN has a bullish consensus with a median price target of $28.00 (ranging from $23.00 to $37.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $20.46, the median forecast implies a 36.9% upside. This outlook is supported by 8 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Paul Knight at Keybanc, projecting a 80.8% upside. Conversely, the most conservative target is provided by Tejas Savant at Morgan Stanley, suggesting a 12.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STVN Analyst Ratings
8
Buy
3
Hold
0
Sell
STVN Price Target Range
Low
$23.00
Average
$28.00
High
$37.00
Current: $20.46
Latest STVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 2, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $24.00 |
| Nov 11, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $26.00 |
| Mar 7, 2025 | UBS | John Sourbeer | Neutral | Maintains | $23.50 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $26.00 |
| Dec 13, 2024 | Wolfe Research | Doug Schenkel | Outperform | Initiates | $28.00 |
| Dec 3, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Assumes | $23.00 |
| Aug 7, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $28.00 |
| Jul 15, 2024 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $22.00 |
| Apr 22, 2024 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $30.00 |
| Mar 25, 2024 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $38.00 |
| Nov 1, 2023 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $30.00 |
| Nov 1, 2023 | Jefferies | David Windley | Hold | Downgrade | $29.00 |
| Sep 26, 2023 | Stephens & Co. | Jacob Johnson | Overweight | Initiates | $33.00 |
| Sep 19, 2023 | CJS Securities | Larry Solow | Market Outperform | Initiates | $36.00 |
| Aug 30, 2023 | Keybanc | Paul Knight | Overweight | Maintains | $37.00 |
| Aug 24, 2023 | Morgan Stanley | Drew Ranieri | Equal-Weight | Downgrade | $34.00 |
| Jul 31, 2023 | Wells Fargo | Overweight | Maintains | $N/A | |
| Jul 31, 2023 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Jul 17, 2023 | Morgan Stanley | Overweight | Reiterates | $N/A | |
| Jun 26, 2023 | Morgan Stanley | Drew Ranieri | Overweight | Reiterates | $29.00 |
Stevanato Group S.p.A. (STVN) Competitors
The following stocks are similar to Stevanato Group based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Stevanato Group S.p.A. (STVN) Financial Data
Stevanato Group S.p.A. has a market capitalization of $5.59B with a P/E ratio of 34.6x. The company generates $1.36B in trailing twelve-month revenue with a 12.0% profit margin.
Revenue growth is +9.1% quarter-over-quarter, while maintaining an operating margin of +17.7% and return on equity of +10.2%.
Valuation Metrics
Market Cap
$5.59B
Enterprise Value
$6.99B
P/E Ratio
34.6x
PEG Ratio
1.9x
Price/Sales
4.8x
Growth & Margins
Revenue Growth (YoY)
+9.1%
Gross Margin
+29.2%
Operating Margin
+17.7%
Net Margin
+12.0%
EPS Growth
+20.1%
Financial Health
Cash/Price Ratio
+2.1%
Current Ratio
1.9x
Debt/Equity
31.4x
ROE
+10.2%
ROA
+5.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Stevanato Group S.p.A. (STVN) Business Model
About Stevanato Group S.p.A.
What They Do
Manufactures medical equipment and supplies.
Business Model
The company operates by providing a comprehensive range of glass primary packaging and integrated solutions for injectable drugs, as well as engineering systems for pharmaceutical manufacturing. It generates revenue through long-term partnerships with pharmaceutical and biotechnology companies, ensuring high customer retention and fostering continuous innovation.
Additional Information
Stevanato Group has a strong global presence in the biopharmaceutical and diagnostic sectors, which positions it as a critical player in the healthcare supply chain. The company focuses on technology-driven solutions and has a rapidly expanding footprint, indicating potential for growth in major global markets.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
5,521
CEO
Mr. Franco Stevanato
Country
Italy
IPO Year
2021
Website
www.stevanatogroup.comStevanato Group S.p.A. (STVN) Latest News & Analysis
Latest News
Quick Summary
Stevanato's biologics drive growth, with strong GLP-1 demand and a solid pipeline. Short-term margin pressure from Engineering is cyclical. Long-term earnings visibility supports a higher target price.
Why It Matters
Stevanato's strong growth in biologics and positive long-term outlook, despite short-term engineering challenges, indicates potential for profitability and stock price recovery, appealing to investors.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Investors in Medical - Drugs stocks should consider Sandoz Group AG (SDZNY) and Stevanato Group (STVN) for potential value opportunities.
Why It Matters
The comparison between Sandoz Group AG and Stevanato Group highlights potential investment opportunities, guiding decisions on value and growth in the pharmaceutical sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in the Medical - Drugs sector may consider Sandoz Group AG (SDZNY) or Stevanato Group (STVN) as potential undervalued stock options.
Why It Matters
The mention of Sandoz and Stevanato as potential undervalued stocks indicates investment opportunities in the Medical - Drugs sector, attracting attention for portfolio diversification.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Stevanato Group S.p.A. (STVN) will hold its Q3 2025 earnings call on November 6, 2025, at 8:30 AM EST, featuring CEO Franco Stevanato and CFO Marco Dal Lago.
Why It Matters
The Q3 earnings call for Stevanato Group may reveal financial performance and strategic insights that can influence stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Stevanato Group (NYSE: STVN) reported Q3 2025 revenue of €303.2 million, a 9% increase year-over-year (11% in constant currency). High-value solutions accounted for 49% of total revenue.
Why It Matters
Stevanato Group's Q3 2025 revenue growth and increased contribution from high-value solutions indicate strong demand and operational efficiency, potentially enhancing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Stevanato Group (STVN) reported Q3 earnings of $0.16 per share, exceeding the Zacks consensus estimate of $0.14 and up from $0.13 per share a year earlier.
Why It Matters
Stevanato Group's earnings beat estimates and grew year-over-year, indicating strong performance and potential for future growth, which can positively influence investor sentiment and stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About STVN Stock
What is Stevanato Group S.p.A.'s (STVN) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, Stevanato Group S.p.A. (STVN) has a median price target of $28.00. The highest price target is $37.00 and the lowest is $23.00.
Is STVN stock a good investment in 2026?
According to current analyst ratings, STVN has 8 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STVN stock?
Wall Street analysts predict STVN stock could reach $28.00 in the next 12 months. This represents a 36.9% increase from the current price of $20.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stevanato Group S.p.A.'s business model?
The company operates by providing a comprehensive range of glass primary packaging and integrated solutions for injectable drugs, as well as engineering systems for pharmaceutical manufacturing. It generates revenue through long-term partnerships with pharmaceutical and biotechnology companies, ensuring high customer retention and fostering continuous innovation.
What is the highest forecasted price for STVN Stevanato Group S.p.A.?
The highest price target for STVN is $37.00 from Paul Knight at Keybanc, which represents a 80.8% increase from the current price of $20.46.
What is the lowest forecasted price for STVN Stevanato Group S.p.A.?
The lowest price target for STVN is $23.00 from Tejas Savant at Morgan Stanley, which represents a 12.4% increase from the current price of $20.46.
What is the overall STVN consensus from analysts for Stevanato Group S.p.A.?
The overall analyst consensus for STVN is bullish. Out of 12 Wall Street analysts, 8 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $28.00.
How accurate are STVN stock price projections?
Stock price projections, including those for Stevanato Group S.p.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 4:26 AM UTC